header
Local cover image
Local cover image
Image from OpenLibrary

A dosing study of intravitreal bevacizumab for retinopathy of prematurity / Nooran Mohamed Abdelhameed ; Supervised Hala Mostafa Elhilali , Hany Salah Hamza , Dina Hossam Hassanein

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Nooran Mohamed Abdelhameed , 2021Description: 61 P. : charts , facsimiles ; 25cmOther title:
  • دراسة جرعات حقن الجسم الزجاجى بمادة البيفازيسيوماب لعلاج اعتلال الشبكية الخداجى [Added title page title]
Subject(s): Online resources: Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Ophthalmology Summary: Purpose: To determine whether a low dose of 0.3125mg intravitreal bevacizumab (IVB) is effective in treatment of type1 retinopathy of prematurity (ROP) as the standard 0.625 mg dose. Methodology: This prospective, comparative, interventional non inferiority study included infants with Type 1 ROP according to ETROP study .The study included 19 infants who were randomly divided into two groups, Group A received 0.3125mg of intravitreal bevacizumab and Group B received 0.625mg of intravitreal bevacizumab. Infants were followed until 60 weeks of postmenstrual age (PMA) to ensure total retinal vascularization and regression of the disease and the need for any rescue therapy. Rescue therapy was defined as the need of a second higher dose of 0.625 mg bevacizumab reinjection or laser at any time during follow up period. Systemic levels of serum vascular endothelial growth factor (VEGF) were also measured using ELISA kits before injection, and after 1 and 4 weeks post injection. Results: A total of 38 eyes of 19 infants were included.Group A included: 18 eyes of 9 infants who received the half dose (0.3125mg intravitreal bevacizumab)
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.24.Ph.D.2021.No.D (Browse shelf(Opens below)) Not for loan 01010110084821000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.24.Ph.D.2021.No.D (Browse shelf(Opens below)) 84821.CD Not for loan 01020110084821000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Ophthalmology

Purpose: To determine whether a low dose of 0.3125mg intravitreal bevacizumab (IVB) is effective in treatment of type1 retinopathy of prematurity (ROP) as the standard 0.625 mg dose. Methodology: This prospective, comparative, interventional non inferiority study included infants with Type 1 ROP according to ETROP study .The study included 19 infants who were randomly divided into two groups, Group A received 0.3125mg of intravitreal bevacizumab and Group B received 0.625mg of intravitreal bevacizumab. Infants were followed until 60 weeks of postmenstrual age (PMA) to ensure total retinal vascularization and regression of the disease and the need for any rescue therapy. Rescue therapy was defined as the need of a second higher dose of 0.625 mg bevacizumab reinjection or laser at any time during follow up period. Systemic levels of serum vascular endothelial growth factor (VEGF) were also measured using ELISA kits before injection, and after 1 and 4 weeks post injection. Results: A total of 38 eyes of 19 infants were included.Group A included: 18 eyes of 9 infants who received the half dose (0.3125mg intravitreal bevacizumab)

Issued also as CD

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image